



Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review

Jayne L. Chamberlain¹ · Saif Huda² · Daniel H. Whittam² · Marcelo Matiello³ · B. Paul Morgan⁴ · Anu Jacob^{2,5}

Published online: 17 October 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: Journal of Neurology
<https://doi.org/10.1007/s00415-019-09498-4>

The original version of this article unfortunately contained a mistake. Fifth sentence of the fourth paragraph in the section “Non-nAChR autoantibody targets in MG” should read as

Cortactin is an intracellular protein involved in signaling downstream of MuSK, so, unlike Lrp4 and agrin, it is difficult to imagine how they might be pathogenic in vivo, without direct access to their intracellular targets.

The original article can be found online at <https://doi.org/10.1007/s00415-019-09498-4>.

✉ Jayne L. Chamberlain
drjlc1000@gmail.com

¹ Ipsen Biopharm Ltd, 9 Ash Rd N, Wrexham LL13 9UF, UK

² Department of Neurology, The Walton Centre, Lower Lane, Liverpool L9 7LJ, UK

³ Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

⁴ School of Medicine, Henry Wellcome Building for Biomedical Research, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK

⁵ University of Liverpool, Liverpool, UK